Editorial: Microbiome in IBD: From Composition to Therapy, Volume II

• Type of Material: Article
• Authors: Ning-Ning Liu, Shanghai Jiao Tong University; Peijian He, Emory University; Zhanju Liu, Tongji University; Ruixin Zhu, Tongji University; Yinglei Miao, Kunming Medical University; Chenggong Yu, Nanjing University; Lixin Zhu, Sun Yat Sen University
• Language: English
• Date: 2023-04-05
• Publisher: FRONTIERS MEDIA SA
• Publication Version: Final Published Version
• Copyright Statement: © 2023 Liu, He, Liu, Zhu, Miao, Yu and Zhu.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3389/fphar.2023.1184269
• Title of Journal or Parent Work: FRONTIERS IN PHARMACOLOGY
• Volume: 14
• Start Page: 1184269
• End Page: 1184269
• Keywords: microbiome; inflammatory bowel disease; interaction; Pharmacology & Pharmacy; Life Sciences & Biomedicine; ulcerative colitis; Science & Technology; Crohn's disease
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Pharmacology

Abstract

Inflammatory bowel disease (IBD) is a chronic, non-specific, immune-mediated, inflammatory intestinal disease, which is divided into ulcerative colitis (UC) and Crohn’s disease (CD). IBD debilitates human physical and psychosocial strength and has a rapidly increasing incidence rate in newly industrialized countries (Ng et al., 2017). Although the etiology of IBD remains unclear, emerging sources of evidence have suggested that gut microbiome may significantly affect the pathogenesis, progression, and prognosis of IBD both in animal models and humans directly and/or indirectly (Ni et al., 2017). Therefore, this Research Topic aims to discuss the alteration of the gut microbiome in IBD and its relationship with the treatment of IBD.